Anti‐SARS‐CoV‐2 vaccines in recipient and/or donor before allotransplant
Abstract
The impact of pre-transplant anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine in 20 recipients of allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and/or their donors is reported here, showing that the persistence of anti-SARS-CoV-2 antibodies can be detected in almost all patients, whatever the type of vaccine used, and up to 9 months post transplant. Also, an anti-SARS-CoV-2 spike glycoprotein CD3+ T-cell response could be detected in six (35%) of 17 evaluable patients. This study provides a rationale to consider anti-SARS-CoV-2 vaccination of both recipients and donors before Allo-HSCT.
Fichier principal
2022 (eJHaem) Anti‐SARS‐CoV‐2 vaccines in recipient and or donor before allotransplant.pdf (203 Ko)
Télécharger le fichier
Origin : Publication funded by an institution